Contineum Therapeutics annual shares outstanding
2022
2023
2024
2025
Contineum Therapeutics Shares Outstanding History (CTNM)
Contineum Therapeutics reported 37.3M shares outstanding at the end of fiscal 2025.
View full Contineum Therapeutics company overviewContineum Therapeutics annual shares outstanding history
| Fiscal year | Period ended | Shares outstanding | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 37.3M | 11.4M | +44.25% |
| 2024 | 2024-12-31 | 25.9M | 23.5M | +1001.13% |
| 2023 | 2023-12-31 | 2.3M | −24.7M | −91.32% |
| 2022 | 2022-12-31 | 27.1M | — | — |
Contineum Therapeutics quarterly shares outstanding
Q4.23
Q1.24
Q2.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Shares outstanding | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 37.6M | 9.6M | +34.13% |
| Q1 2026 | 2026-03-31 | 37.4M | 11.5M | +44.51% |
| Q4 2025 | 2025-12-31 | 37.3M | 11.4M | +44.25% |
| Q3 2025 | 2025-09-30 | 23.1M | — | — |
| Q2 2025 | 2025-06-30 | 28.0M | 9.0M | +47.63% |
| Q1 2025 | 2025-03-31 | 25.9M | 23.5M | +985.02% |
| Q4 2024 | 2024-12-31 | 25.9M | 23.5M | +1001.13% |
| Q2 2024 | 2024-06-30 | 19.0M | — | — |
| Q1 2024 | 2024-03-31 | 2.4M | — | — |
| Q4 2023 | 2023-12-31 | 2.3M | — | — |
Contineum Therapeutics Share Buyback History
A share buyback, also called a stock repurchase, is when a company uses cash to buy its own shares. Contineum Therapeutics share buyback history shows the reported cash used for repurchases. Buybacks can reduce shares outstanding, but issuance, stock-based compensation, acquisitions, and stock splits can change the share count separately.
Contineum Therapeutics used $0 to repurchase common stock in fy 2024. Across the latest 4 reported fiscal years, total share repurchases were $32,000.
| Fiscal year | Period ended | Share repurchases |
|---|---|---|
| 2024 | 2024-12-31 | $0 |
| 2023 | 2023-12-31 | $28,000 |
| 2022 | 2022-12-31 | $4,000 |
| 2021 | 2021-12-31 | $0 |
TickerStat uses SEC-reported cash payments for common-stock repurchases. The amounts describe capital returned through buybacks; they are not a forecast or a measure of the number of shares retired.
Contineum Therapeutics shares outstanding trends
Between the periods ended 2022-12-31 and 2025-12-31, Contineum Therapeutics's shares outstanding moved from 27.1M to 37.3M, a change of 10.3M. The latest reported quarter, Q2 2026, shows 37.6M.
About the metric
What shares outstanding means
Shares outstanding is the number of common shares held by investors at a reporting-period end. The count can change because of stock issuance, repurchases, conversions, acquisitions, or stock splits.
Calculation and source
SEC-reported period-end shares
TickerStat displays period-end common shares from SEC filings and adjusts older values to the current share basis when a stock-split conversion ratio is reported directly or evidenced by a later filing’s restated historical share balance. After repeated reverse splits, an old period can represent less than one current-basis share; this is a split-adjusted equivalent, not a literal historical certificate count. Values remain as reported when no reliable split ratio is available. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Contineum Therapeutics source filings ↗